You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Budesonide and nedocromil did not improve lung function in children with asthma

https://doi.org/10.1136/ebm.6.3.84

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) N Engl J Med 343, 1054. The Childhood Asthma Management Program Research Group.. Long-term effects of budesonide or nedocromil in children with asthma.. Oct 12;. :. –63.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In children with asthma, does continuous, long term treatment with budesonide or nedocromil improve lung function

    Design

    Randomised {allocation concealed*}†, {partially blinded (active treatment v placebo was blinded, but mode of treatment [steroid v non-steroid] was not)}†,* controlled trial with mean 4.3 years of follow up.

    Setting

    8 clinical centres in the US and Canada.

    Patients

    1041 children who were 5–12 years of age (mean age 9 y, 60% boys), had mild to moderate asthma, and had no other clinically significant condition. Follow up was 98% for lung function and ≥86% for diary outcomes.

    Intervention

    Patients were allocated to 1 of 2 active agents or a matching placebo. Active agents were budesonide, 200 μg twice daily in two 100 μg puffs from a metered dose inhaler …

    View Full Text

    Footnotes

    • Sources of funding: National Heart, Lung, and Blood Institute and National Center for Research Resources. Drugs were provided by AstraZeneca; Glaxo Research Institute; Rhone-Poulenc Rorer.

    • For correspondence: Dr J Tonascia, CAMP Coordinating Center, Johns Hopkins University, 615 North Wolfe Street, Room 5010, Baltimore, MD 21205, USA.

    • ↵* See glossary.

    • ↵† Information provided by author.